-$0.73 EPS Expected for G1 Therapeutics Inc (NASDAQ:GTHX) This Quarter

Share on StockTwits

Equities research analysts predict that G1 Therapeutics Inc (NASDAQ:GTHX) will post earnings of ($0.73) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.67) and the lowest is ($0.85). G1 Therapeutics reported earnings per share of ($0.64) in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.1%. The business is expected to announce its next earnings results on Wednesday, August 14th.

On average, analysts expect that G1 Therapeutics will report full year earnings of ($2.89) per share for the current financial year, with EPS estimates ranging from ($3.14) to ($2.67). For the next financial year, analysts anticipate that the company will report earnings of ($3.71) per share, with EPS estimates ranging from ($4.60) to ($3.26). Zacks’ EPS calculations are an average based on a survey of analysts that follow G1 Therapeutics.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Thursday, May 9th. The company reported ($0.64) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.05.

Several equities research analysts recently issued reports on the company. BidaskClub downgraded Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a report on Monday, June 24th. Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Finally, Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. G1 Therapeutics currently has a consensus rating of “Buy” and an average price target of $60.43.

NASDAQ:GTHX traded up $0.82 on Wednesday, reaching $26.52. The company’s stock had a trading volume of 4,852 shares, compared to its average volume of 494,523. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $69.57. The firm has a market capitalization of $962.91 million, a price-to-earnings ratio of -10.43 and a beta of 2.68. The company has a 50 day moving average of $24.70.

Several hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its holdings in G1 Therapeutics by 52.9% during the 4th quarter. Rhumbline Advisers now owns 28,246 shares of the company’s stock valued at $541,000 after buying an additional 9,772 shares during the period. BlackRock Inc. increased its position in shares of G1 Therapeutics by 6.9% in the fourth quarter. BlackRock Inc. now owns 1,963,714 shares of the company’s stock valued at $37,604,000 after buying an additional 126,892 shares in the last quarter. Northern Trust Corp increased its position in shares of G1 Therapeutics by 7.4% in the fourth quarter. Northern Trust Corp now owns 281,680 shares of the company’s stock valued at $5,393,000 after buying an additional 19,360 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of G1 Therapeutics in the fourth quarter valued at approximately $1,570,000. Finally, Geode Capital Management LLC increased its position in shares of G1 Therapeutics by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 279,063 shares of the company’s stock valued at $5,344,000 after buying an additional 26,098 shares in the last quarter. Hedge funds and other institutional investors own 73.35% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Featured Article: S&P 500 Index

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report